EPISODE · Jan 28, 2025 · 19 MIN
30 Day FDA and ICH Drug Development Regulations - Day 3 Pre-Clinical Development
from Cannabinoid and Psychedelic Pharmacology and Drug Development
In this episode, we delve into the fascinating world of pre-clinical drug development—the critical stage where scientists determine whether a drug is safe and effective enough to move to human trials. Often overlooked, this phase lays the groundwork for every new medical breakthrough. We explore: - The rigorous pre-clinical studies, including safety pharmacology, toxicology, PK/PD (pharmacokinetics and pharmacodynamics), and genotoxicity testing. - The role of the Investigational New Drug (IND) application, the gateway to human trials, and its key components like safety data, manufacturing processes, and clinical trial protocols. - The ethical challenges of animal testing and the promising rise of alternatives like in vitro studies and computer modeling. - Insights into how biostatistics shapes the understanding of pre-clinical data, ensuring the findings are reliable and meaningful. Discover how the U.S. Code of Federal Regulations (CFR), Title 21, provides the framework for pre-clinical safety and why this phase is vital in bringing safe, effective drugs to market. Takeaway Thought: Pre-clinical development may be behind the scenes, but it’s where the journey begins—filled with challenges, innovation, and the hope of life-changing discoveries. Stay curious, keep learning, and join us as we uncover the meticulous effort behind every medical breakthrough!
Embed this episode
NOW PLAYING
30 Day FDA and ICH Drug Development Regulations - Day 3 Pre-Clinical Development
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.